

KING & SPALDING

**Huron**LifeSciences

---

Managed Markets  
Government Payers and Providers  
An Overview from the Pharmaceutical Manufacturer  
Perspective

June 8, 2016



Chris Coburn  
Managing Director  
Huron Consulting Group  
ccobourn@huronconsultinggroup.com  
312-212-6710



John Shakow  
Partner  
King & Spalding  
jshakow@kslaw.com  
202-626-5523

# The Programs and the Populations they Serve

# The “Government Customer”

---

- The government pays for or reimburses providers for drugs distributed to American beneficiaries based on beneficiaries’ eligibility for various Government Programs
- Nearly 50% of Americans receive some benefit through a Government Program

Medicaid

Medicare

VA/FSS

PHS/340B

# As Gov't Programs Grow and Increase Their Buying Power, Compliance is Becoming a Major Focus

---

## Growth in Gov't Healthcare Programs

- Government healthcare programs, such as Medicaid and Medicare continue to grow
- Over 50% of Americans are expected to receive some benefit from a publicly funded program

## Manufacturer Compliance with Gov't Programs

- As a result of increasing drug spend, federal and state governments are focusing more on manufacturer compliance
- The Office of Inspector General (OIG) oversees the federal programs with the mandate to “protect the integrity of the programs”
  - Can apply the False Claims Act if data (statutory pricing calculations) reported to the government causes the government to pay more than they should for a manufacturers products
  - Manufacturers are expected to have processes, systems and controls in place to ensure the accuracy of their calculations
  - The calculations are very complex, and in many cases guidance is insufficient and/or unclear, and manufactures must make reasonable assumptions

# Overview of Agencies and Oversight

Federal Administration:

<b>CMS</b> Medicaid (AMP, BP) Medicare B (ASP) Medicare D (CGDP)	<b>VA</b> Federal Supply Schedule (FSS) (NonFAMP, FCP)	<b>OPA</b> 340B (PHS Price PHS & DSH Eligibility)	<b>DoD</b> Tricare
---	---	--	-----------------------

State Administration:

<b>State Medicaid Agencies</b> Medicaid (State eligibility and membership, Pharmaceutical Mfg Rebates) State Pharmaceutical Assistance Programs, Supplemental Programs
---

Investigation / Enforcement:

<b>Office of Inspector General (OIG)</b> Audit and Investigation, Compliance with Programs (OIG Work Plan, response to Whistleblower cases)
<b>Department of Justice (DOJ)</b> Investigation, violations of law, prosecution
<b>States</b> State Attorneys General, NAMFCU, Medicaid Integrity

# Impact of Commercial Activity on Government Pricing


---

Government Pricing Calculations are based upon Commercial Activity.

The calculations are based upon net prices to certain Classes of Trade and discounts to those customers.

- Classes of Trade that are included and excluded from a specific type of calculation
- Determination of fees paid, and whether they constitute a Bona Fide Service Fee and may be excluded from a calculation (or Service Fee for VA), or treated as a discount.

# GP and Commercial Relationships





# Providers vs Payers/Purchasers

---

## Providers

(reimburse after utilization, retail based)

- **Medicaid:** Outpatient program, with states reimbursing pharmacies for units dispensed to eligible patients, a quarterly rebate paid to the state by manufacturers for Medicaid units dispensed in the quarter
- **Medicare:**
  - Part D – Outpatient based program, with eligible patients receiving benefits in the retail setting (co-pay, based on eligibility), with a commercially determined rebate paid to the plans for utilization
  - Medicare Part B - Reimbursement for physician administered drugs (as there is no retail prescription)
- **Tricare:** Outpatient benefits for military dependents and families, a manufacturer rebate paid based upon units dispensed


## Payers/Purchasers

(up front discount, usually indirect)




- **VA:** Federal Agencies purchasing at the package level from Wholesalers (for inpatient/outpatient inventory)
- **PHS/340B:** Eligible entities purchasing at the package level from Wholesalers for outpatient use

# General Environment For Purchasing and Reimbursement Under Government Programs

## Federal Programs & the Populations They Serve



Note: 340B entities can serve Medicaid patients but manufacturers either pay a Medicaid rebate *or* offer a 340B price – not both.

-  Quarterly Unit base Reimbursement
-  Up Front Purchase, Package Level
-  Reimbursement to Physicians/Clinics


# Medicaid Drug Rebate Program (“MDRP”)

---

- The MDRP is administered by the Centers for Medicare and Medicaid Services (CMS) and is jointly funded by states and the Federal government.
- Manufacturers sign the national Medicaid Drug Rebate Agreement, which along with statute and regulations, defines their responsibilities.
- Medicaid provides prescription and over-the-counter drug coverage to:
  - Low-income individuals and families
  - Individuals with disabilities
  - Individuals/families with inadequate insurance
- **Over 50 million Americans are Medicaid beneficiaries**
- Broad national guidelines established Federal statutes, regulations and policies. States have flexibility to design their programs and may:
  - Establish eligibility standards
  - Determine what benefits and services to cover
  - Set reimbursement rates




# Medicaid Program Flow - Operations



# Pricing Example – Determining the URA

Medicaid prices are calculated at the unit level



- Branded Drugs (S/I):  $URA = AMP * 23.1\%$  or  $AMP - BP$ , whichever is greater
- Generic Drugs (N):  $URA = AMP * 13\%$

# Medicare

---

Medicare provides health insurance to certain individuals over the age of 65 and is also administered by CMS.\* Medicare is split into four main parts:

- **Part A** – Health Insurance covers hospital stays and skilled nursing home care.
- **Part B** – Medical Insurance covers doctors' services, outpatient hospital care, physician administered drugs (often referred to as ASP drugs) and other medical services not covered under Part A.
- **Part C** – Medicare Advantage Plans offer beneficiaries the option to enroll in private health insurance plans that may cover expenses not covered under Part A and Part B. Medicare pays a capitated rate to the private insurer and the beneficiary typically pays an additional premium.
- **Part D** - Prescription Drug Plan intended to offset the costs of outpatient, non – physician administered prescription drugs. Medicare beneficiaries must enroll in either a stand-alone Prescription Drug Plan (PDP) or a Medicare Advantage plan with prescription coverage (MA-PD) in order to participate in Part D. Part D plans are privately designed and administered. Manufacturer rebates to PDPs/MA-PDs are commercially negotiated and are Medicaid Best Price exempt.

\*Medicare is the single largest purchaser of drugs in the US, Wall Street Journal

# Dual Eligibles

---

- Eligible for both Medicare and Medicaid
  - Medicare is primary payer
  - Medicaid is secondary payer and picks up partial, but invoices Manufacturer for full rebate
  - Nearly 10 million Americans
  - 14% of Medicaid enrollment, with approximately 36% of Medicaid spend
  - 20% of Medicare enrollment, with approximately 31% of Medicare dollars



# Federal Supply Schedule Program

---

- The pharmaceutical schedule of the Federal Supply Schedule (“FSS”) Program is administered by the Department of Veterans Affairs (“VA”).
- The FSS is intended to provide Federal entities with a simplified means to purchase goods at negotiated prices that are based on those paid by a manufacturer’s non-federal “most favored customer.”
- Agencies referred to as the “Big 4,” (VA, Department of Defense, Coast Guard, and PHS [including Indian Health Services]) are entitled to purchase innovator prescription drugs at a Federal Ceiling Price (“FCP”) which can be lower than or equal to the FSS price, which is available to non-Big 4 Federal Purchasers. .
- Federal purchases are typically indirect purchases made through a wholesaler.
- Manufacturers *must* make their brand-name drugs (including authorized generics) available at the FSS price if they participate in the Medicaid program.
- Participation in the FSS program is optional for generic drugs.






# 340B Drug Discount Program

---

Veterans Health Care Act of 1992 enacted section 340B of the Public Health Service Act (“PHS Act”), which created the “Limitation of Prices of Drugs Purchased by Covered Entities.”

- Section 340B provides that a manufacturer who sells covered outpatient drugs to certain eligible entities agrees to charge a price for covered outpatient drugs that will not exceed that determined under a statutory formula (also referred to as the ceiling price).
- 340B covered entities are Disproportionate Share Hospitals, Federal Grantee Clinics, and other safety net entities.
- Manufacturers are required to communicate this price to wholesalers and distributors, but at this time government reporting of the 340B price is not required.
- The Office of Pharmacy Affairs (“OPA”), which falls under the Health Resource and Services Administration (“HRSA”) an agency of the Department of Health and Human Services (“HHS”), administers the 340B Drug Pricing Program.
- Manufacturers that participate in Medicaid must participate in the 340B pricing program for both brand and generic drugs.
- To enter the program, a manufacturer signs a Pharmaceutical Pricing Agreement (“PPA”) with HRSA.
- 340B purchases are typically indirect purchases made through a wholesaler.
- 340B entities may charge patients more for drugs than their discounted acquisition prices, earning a spread on each sale.

# Medicaid Pricing Components then Determine the 340B Price, for Eligible 340B entities



- 340B Price = AMP minus the URA, times Units Per Package

Program	Population	Details
Medicaid (and MMCO coverage)	<ul style="list-style-type: none"> <li>State administered program providing <u>outpatient</u> based drug benefits to the poor (all ages)</li> <li>Serves over 50 million Americans.</li> </ul>	<ul style="list-style-type: none"> <li>Manufacturers pay quarterly rebates to the states, the rebates are based upon the URA, calculated off of the reported AMP and BP</li> </ul>
Medicare D	<ul style="list-style-type: none"> <li><u>Outpatient</u> based prescription drug benefit for the elderly</li> <li>Serves 47 million, growing to 80 million by 2030</li> </ul>	<ul style="list-style-type: none"> <li>Manufacturers participate in plans, providing rebates based upon utilization</li> <li>Manufacturers also pay 50% during the coverage gap</li> </ul>
Medicare B (ASP)	<ul style="list-style-type: none"> <li>Reimbursement to physicians for drugs administered to Medicare patients in physician's office</li> </ul>	<ul style="list-style-type: none"> <li>Reimbursement to physicians typically equal to 106% of volume weighted ASPs within the payment code</li> </ul>
340B Drug Discount Program	<ul style="list-style-type: none"> <li>Provides covered <u>outpatient</u> drugs at reduced pricing to eligible 340B covered entities</li> </ul>	<ul style="list-style-type: none"> <li>Eligible entities purchase from wholesalers at the 340B price (Manufacturer receives a chargeback)</li> </ul>
VA/FSS	<ul style="list-style-type: none"> <li>Mechanism for the Federal government to purchase drugs</li> </ul>	<ul style="list-style-type: none"> <li>Eligible entities purchase from wholesalers at the FSS or FCP price (Manufacturer receives a chargeback)</li> </ul>
TRICARE Retail Pharmacy Program (TRRx)	<ul style="list-style-type: none"> <li>A program which provides outpatient pharmacy services to TRICARE beneficiaries</li> </ul>	<ul style="list-style-type: none"> <li>Drugs dispensed by the TRRx are subject FCP limitations</li> <li>Manufacturers pay quarterly TRICARE rebates</li> </ul>

# The Many Prices of a Drug

# The Many Prices of a Drug

Average Wholesale Price (AWP)

Wholesale Acquisition Cost (WAC)

Average Sales Price (ASP)

Average Manufacturer Price (AMP)


Non Federal AMP (Non-FAMP)

Best Price (BP)



# The Many Prices of a Drug

## Average Wholesale Price (AWP)



Not really the average of anything; a markup by publishers of 20% over list price; former benchmark for Medicare reimbursement; current benchmark for some states' Medicaid reimbursement (single source drugs) and commercial contracting

# The Many Prices of a Drug

Wholesale Acquisition Cost (WAC)

Undiscounted list price set by the manufacturer; basis of AWP; defined in federal law in 2003

# The Many Prices of a Drug



## Average Sales Price (ASP)

Basis for Medicare physician administered outpatient drug reimbursement; calculated quarterly by the manufacturer and submitted to CMS (certified); employs 12-month rolling average



# The Many Prices of a Drug

Basis for the Medicaid rebate and the 340B price; two methodologies for calculation (standard and 5i); calculated monthly and quarterly by manufacturer and submitted to CMS (certified); employs a 12-month rolling average

Average Manufacturer Price (AMP)



# The Many Prices of a Drug

Potentially the basis of the FSS price; average non-federal price; calculated quarterly and annually by the manufacturer and submitted to the VA (not certified); no rolling average; not generally subject to updating or resubmission

Non Federal AMP (Non-FAMP)



# The Many Prices of a Drug


Very important part of the Medicaid rebate calculation for innovator products; the single best price commercially available; determined quarterly by the manufacturer and submitted to CMS (certified); not an average; must be updated and refiled over time



Best Price (BP)

# The Many Prices of a Drug

- What makes the prices different from one another?
  - How they are used
    - Set price (Non-FAMP)
    - Set rebate (AMP and BP)
    - Set reimbursement (ASP)
  - How they are calculated
    - Classification & Filtering
    - Mechanisms for addressing temporal disconnect
      - Refiling (BP)
      - Rolling average methodology (AMP and ASP)
  - How they can be restated
    - As needed within 3 years (AMP and BP)
    - No mechanism for restatement (ASP and Non-FAMP)



# HuronLifeSciences

Innovative Life Science  
Strategies and Risk Mitigation.  
It's in our DNA.